Recent Updates
Recently added Catalysts

TERN-201

Phase 1

NASH - Nonalcoholic Steatohepatitis | Small molecule | Infectious Disease |Terns Pharmaceuticals, Inc.|Last Updated: Jun 6, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment52
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04897594AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic SteatohepatitisPHASE1 COMPLETED 52 — — May 1, 2021Sep 1, 2022Jun 6, 2024 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
TERN-201DRUGInvestigational drug
PlaceboOTHERMatching placebo
Unlock Study Design Details